Small molecule inhibitors for ALK, ROS1, and NTRK fusions, such as crizotinib, brigatinib, lorlatinib, entrectinib and larotrectinib, have been approved by the US Food and Drug Administration (FDA) for different cancer types (16–20). Here, ALK is linked to cancer.